Anhui Province Hospital

The trials here

What the 13 trials at this site are about, from their registry records.

Conditions

• Liver and biliary tract cancer3 trials
• Lung cancer3 trials
• Cervical cancer2 trials
• Atrial fibrillation1 trial
• Colorectal cancer1 trial
• Coronary artery disease1 trial
• Crohn's disease1 trial
• Haemophilia1 trial

Phase

• Phase 35 trials
• Phase 23 trials
• Phase 1/21 trial
• Phase 41 trial

Status

• Recruiting5 trials
• Completed3 trials
• Not yet recruiting3 trials
• Active, not recruiting2 trials

Lead sponsor

• Anhui Provincial Hospital6 trials
• Janssen Research & Development, LLC3 trials
• Biotheus Inc.1 trial
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.1 trial
• Haihe Biopharma Co., Ltd.1 trial
• and 1 more

Running trials

• Not yet recruiting

  Perioperative Adebrelimab for Locally Advanced Cervical Cancer

  NCT07811375· Phase 2· Anhui Provincial Hospital· Source

  Contact: Yi Liu

• Not yet recruiting

  Postoperative ctHPV-DNA for Recurrence Prediction and Adjuvant Treatment Decision-Making in Cervical Cancer

  NCT07782697· Anhui Provincial Hospital· Source

  Contact: Yi Liu

• Recruiting

  China Liver Cancer Clinical Registry Cohort Database (HEAL)

  NCT06777485· Anhui Provincial Hospital· Source

  Contact: Ji-Zhou Wang, MD PhD

• Recruiting

  Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma

  NCT06664021· Phase 2· Anhui Provincial Hospital· Source

  Contact: Ji-Zhou Wang, M.D.

• Active, not recruiting

  PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer

  NCT06616532· Phase 3· Biotheus Inc.· Source

• Recruiting

  Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab

  NCT06498622· Phase 2· Anhui Provincial Hospital· Source

  Contact: Lianxin Liu, M.D.

• Recruiting

  Local Liver Treatment for Multi-organ Colorectal Cancer Metastases

  NCT06449937· Anhui Provincial Hospital· Source

  Contact: Ji-Zhou Wang, MD PhD

• Recruiting

  D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

  NCT06300177· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

  Contact: Minghong Bao, Master

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

  NCT04270591· Phase 1/2· Haihe Biopharma Co., Ltd.· Source

  Contact: Lejie Cao

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Liver and biliary tract cancer3 recruiting
• Cervical cancer2 recruiting
• Lung cancer2 recruiting
• Colorectal cancer1 recruiting

Closed trials

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A

  NCT05707351· Phase 3· Takeda· Source

• Completed

  A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease

  NCT05029921· Phase 4· Janssen Research & Development, LLC· Source